ALPHS — Pharmasimple SA Income Statement
0.000.00%
Last trade - 00:00TechnologyHighly SpeculativeMicro Cap
Annual income statement for Pharmasimple SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
C2016 December 31st | 2017 December 31st | 2018 December 31st | 2019 December 31st | 2020 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | BAS | BAS | BAS | BAS | BAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 11.3 | 19.1 | 16.8 | 28.2 | 45.5 |
| Cost of Revenue | |||||
| Gross Profit | 1.94 | 3.12 | 3.17 | 4.96 | 10.5 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 12.1 | 20.4 | 19.1 | 31.3 | 46.9 |
| Operating Profit | -0.741 | -1.29 | -2.32 | -3.03 | -1.38 |
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.942 | -1.37 | -2.44 | -3.18 | -1.53 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -0.941 | -1.37 | -2.44 | -3.19 | -1.53 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.941 | -1.37 | -2.44 | -3.17 | -1.52 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.941 | -1.37 | -2.44 | -3.17 | -1.52 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -33,801 | -44,618 | -94,565 | -53,937 | -24,846 |